ACE and kidney disorder: There are several promising ongoing clinical trials [7]; however, until novel therapies are available, the 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines [8] recommend renin-angiotensin system (RAS) blockade, either angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor inhibitors (ARB), as the cornerstone of supportive therapy for IgAN.